On May 18, 2023, David Setboun, PhD, MBA, Executive Vice President and Chief Operating Officer of Brainstorm Cell Therapeutics Inc. notified the Company of his decision to resign from his role effective as of May 31, 2023 to pursue another opportunity. Dr. Setboun's decision to resign was not due to any disagreement with the Company on any matter, or relating to its operations, policies, or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.516 USD | +6.61% | +10.49% | +89.01% |
Apr. 17 | Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024 | CI |
Apr. 17 | Brainstorm Cell Therapeutics Inc. Announces Management Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+89.01% | 35.26M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+50.24% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- BCLI Stock
- News Brainstorm Cell Therapeutics Inc.
- Brainstorm Cell Therapeutics Inc Announces Resignation of David Setboun as Executive Vice President and Chief Operating Officer